JP2023552462A5 - - Google Patents

Info

Publication number
JP2023552462A5
JP2023552462A5 JP2023534636A JP2023534636A JP2023552462A5 JP 2023552462 A5 JP2023552462 A5 JP 2023552462A5 JP 2023534636 A JP2023534636 A JP 2023534636A JP 2023534636 A JP2023534636 A JP 2023534636A JP 2023552462 A5 JP2023552462 A5 JP 2023552462A5
Authority
JP
Japan
Application number
JP2023534636A
Other languages
Japanese (ja)
Other versions
JPWO2022125566A5 (https=
JP2023552462A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/062238 external-priority patent/WO2022125566A1/en
Publication of JP2023552462A publication Critical patent/JP2023552462A/ja
Publication of JP2023552462A5 publication Critical patent/JP2023552462A5/ja
Publication of JPWO2022125566A5 publication Critical patent/JPWO2022125566A5/ja
Pending legal-status Critical Current

Links

JP2023534636A 2020-12-08 2021-12-07 半減期延長組成物および方法 Pending JP2023552462A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063122818P 2020-12-08 2020-12-08
US63/122,818 2020-12-08
PCT/US2021/062238 WO2022125566A1 (en) 2020-12-08 2021-12-07 Half-life extending compositions and methods

Publications (3)

Publication Number Publication Date
JP2023552462A JP2023552462A (ja) 2023-12-15
JP2023552462A5 true JP2023552462A5 (https=) 2024-12-12
JPWO2022125566A5 JPWO2022125566A5 (https=) 2024-12-12

Family

ID=81973740

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023534636A Pending JP2023552462A (ja) 2020-12-08 2021-12-07 半減期延長組成物および方法

Country Status (9)

Country Link
US (1) US20240034814A1 (https=)
EP (1) EP4259178A4 (https=)
JP (1) JP2023552462A (https=)
KR (1) KR20230156897A (https=)
CN (1) CN117042788A (https=)
AU (1) AU2021397734A1 (https=)
CA (1) CA3201560A1 (https=)
MX (1) MX2023006732A (https=)
WO (1) WO2022125566A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2021287998B2 (en) 2020-06-11 2026-03-12 Benaroya Research Institute At Virginia Mason Methods and compositions for preventing type 1 diabetes
AU2021396172A1 (en) 2020-12-09 2023-07-06 Janux Therapeutics, Inc. Compositions and methods related to tumor activated antibodies targeting psma and effector cell antigens
US12565529B2 (en) 2021-05-24 2026-03-03 Provention Bio, Inc. Methods for treating type 1 diabetes
GB2641580A (en) 2024-06-07 2025-12-10 T Therapeutics Ltd Tumour-transforming multispecific proteins

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1355919E (pt) * 2000-12-12 2011-03-02 Medimmune Llc Moléculas com semivida longa, composições que as contêm e suas utilizações
WO2004041867A2 (en) * 2002-11-08 2004-05-21 Ablynx N.V. Camelidae antibodies against imminoglobulin e and use thereof for the treatment of allergic disorders
SG173488A1 (en) * 2009-02-19 2011-09-29 Glaxo Group Ltd Improved anti-serum albumin binding variants
CN111433224B (zh) * 2017-11-17 2024-03-19 南京传奇生物科技有限公司 抗pd-l1的单结构域抗体及其变体
WO2019204925A1 (en) * 2018-04-24 2019-10-31 National Research Council Of Canada Serum albumin binding antibodies for tuneable half-life extension of biologics
CN113508134B (zh) * 2019-02-22 2024-12-03 安维达生物科技公司 白蛋白结合抗体及其用途

Similar Documents

Publication Publication Date Title
JP2023531494A5 (https=)
JP2023552462A5 (https=)
CN305672589S (https=)
CN305595638S (https=)
CN305534563S (https=)
CN305534161S (https=)
CN305533482S (https=)
CN305534668S (https=)
CN305531075S (https=)
CN305530656S (https=)
CN305530541S (https=)
CN305545293S (https=)
CN305528803S (https=)
CN305528553S (https=)
CN305546724S (https=)
CN305528198S (https=)
CN305740559S (https=)
CN305738995S (https=)
CN305738696S (https=)
CN305736576S (https=)
CN305733365S (https=)
CN305727601S (https=)
CN305547028S (https=)
CN305548150S (https=)
CN305727377S (https=)